Clinical Trial Update: Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC [Phase 2]

View source ↗

Summary

Phase II study evaluating sorafenib in combination with carboplatin and docetaxel as first-line treatment for advanced non-small cell lung cancer has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22